Menu
Learn more about the activities, events, and news of e-llas.
After launching the call for our open innovation initiative in February during the 4YFN event and following the registration phase of the program, the application submission period closed on May 10.
A trend study was carried out with the purpose of exploring the main areas of innovation in cancer treatment, especially in the specific case of gynecological cancer.
In the recent edition of 4YFN (Four Years From Now), we launched our open innovation call in gynaecological cancer. Discover how the event was in this article!
Improving diagnostic methods and population screening is essential to increase patient survival.
Comprehensive support involves addressing the needs of patients in all areas of their lives, from nutrition and exercise to sexuality, fertility, and emotional or workplace support.
At GSK, we have a unifying purpose: to transform cancer into HOPE. That’s why e-llas is born.
Together with our partners and collaborators, we conducted an internal innovation session where we defined the challenges of e-llas. Getting closer to finding solutions!
Open innovation can facilitate a collaborative environment that transcends traditional R&D barriers, allowing for more agile advances in early detection, treatment, and monitoring of pathologies.
For more information, please contact your healthcare professional.
NP-ES-AOU-WCNT-240001 (v1) 02/2024